Bradley S. Galer
Direttore Tecnico/Scientifico/R&S presso Rapport Therapeutics, Inc.
Patrimonio netto: 4 M $ in data 31/05/2024
Profilo
Bradley S.
Galer is currently the Director at Zogenix International Ltd.
since 2016 and the Chief Medical Officer at Rapport Therapeutics, Inc. since 2023.
Previously, he served as the President-Pain Group at Nuvo Pharmaceuticals, Inc. from 2009 to 2013, the Chief Medical Officer & Executive Vice President at Zogenix, Inc. from 2013 to 2022, and the Senior Medical Officer & VP-Scientific Affairs at Endo Pharmaceuticals, Inc. from 2002 to 2005.
He also held academic positions as an Associate Professor at Albert Einstein College of Medicine, Inc. and as an Assistant Professor at UW Medicine.
Dr. Galer holds a doctorate degree from Albert Einstein College of Medicine, Inc. and an undergraduate degree from Wesleyan University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
Rapport Therapeutics, Inc.
 Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. 0.56% | 06/06/2024 | 197 426 ( 0.56% ) | 4 M $ | 31/05/2024 |
Posizioni attive di Bradley S. Galer
| Società | Posizione | Inizio |
|---|---|---|
Zogenix International Ltd.
 Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Direttore/Membro del Consiglio | 15/08/2016 |
Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. BiotechnologyHealth Technology Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA. | Direttore Tecnico/Scientifico/R&S | 01/01/2023 |
Precedenti posizioni note di Bradley S. Galer
| Società | Posizione | Fine |
|---|---|---|
| ZOGENIX, INC. | Direttore Tecnico/Scientifico/R&S | 01/06/2022 |
| NUVO PHARMACEUTICALS INC. | Corporate Officer/Principal | 01/12/2013 |
Endo Pharmaceuticals, Inc.
 Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | Direttore Tecnico/Scientifico/R&S | 01/10/2005 |
| Albert Einstein College of Medicine, Inc. | Corporate Officer/Principal | - |
| UW Medicine | Corporate Officer/Principal | - |
Formazione di Bradley S. Galer
| Albert Einstein College of Medicine, Inc. | Doctorate Degree |
| Wesleyan University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
 | Health Technology |
| Aziende private | 4 |
|---|---|
Nuvo Pharmaceuticals, Inc.
 Nuvo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
Endo Pharmaceuticals, Inc.
Endo Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Endo Pharmaceuticals, Inc. manufactures and distributes pharmaceutical products. The company provides research and development of generic pharmaceutical products for controlling pain. Its product includes Lidoderm, Percocet, Percodan, Frova, DepoDur, and Zydone. The company is headquartered in Malvern, PA. | Health Technology |
Zogenix International Ltd.
Zogenix International Ltd. Pharmaceuticals: MajorHealth Technology Zogenix International Ltd. manufactures and markets pharmaceutical products. It develops Brabafen an oral treatment for use in children with Dravet Syndrome or severe myoclonic epilepsy of infancy. The company was founded in 2012 and is headquartered in Maidenhead, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Bradley S. Galer
